December 2002
Volume 43, Issue 13
Free
ARVO Annual Meeting Abstract  |   December 2002
Photodynamic Therapy for Choroidal Neovascularization Following Thermal Laser Treatment
Author Affiliations & Notes
  • JC Wickens
    Ophthalmology Washington University St Louis MO
  • M Busquets
    Barnes Retina Institute St Louis MO
  • G Shah
    Barnes Retina Institute St Louis MO
  • K Blinder
    Barnes Retina Institute St Louis MO
  • I Boniuk
    Barnes Retina Institute St Louis MO
  • D Burgess
    Barnes Retina Institute St Louis MO
  • MG Grand
    Barnes Retina Institute St Louis MO
  • NM Holekamp
    Barnes Retina Institute St Louis MO
  • D Joseph
    Barnes Retina Institute St Louis MO
  • MA Thomas
    Barnes Retina Institute St Louis MO
  • Footnotes
    Commercial Relationships   J.C. Wickens, None; M. Busquets, Novartis R; G. Shah, None; K. Blinder, None; I. Boniuk, None; D. Burgess, None; M.G. Grand, None; N.M. Holekamp, None; D. Joseph, None; M.A. Thomas, None.
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 604. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      JC Wickens, M Busquets, G Shah, K Blinder, I Boniuk, D Burgess, MG Grand, NM Holekamp, D Joseph, MA Thomas; Photodynamic Therapy for Choroidal Neovascularization Following Thermal Laser Treatment . Invest. Ophthalmol. Vis. Sci. 2002;43(13):604.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose:To determine if photodynamic therapy (PDT) with verteporfin is a feasible treatment option for stabilization of vision in patients with recurrent or persistent choroidal neovascularization (CNV) that have previously received thermal laser treatment. Methods:A retrospective analysis of 34 eyes of 34 patients that received PDT subsequent to treatment of CNV with argon or krypton laser photocoagulation was performed. Patients that have received submacular surgery were excluded. Demographic, angiographic, and visual outcome data were analyzed. Results:The diagnosis of CNV was primarily associated with age-related macular degeneration (75%) presumed ocular histoplasmosis (12%), myopic degeneration (9%) and idiopathic (3%). Data collected with average follow-up of 9 months showed 12 (35%) eyes had a doubling of the visual angle while 22 (65%) lost less than a doubling of the visual angle. When compared to a natural history group the relative risk was 0.658 (p-value=0.036). Mean number of PDT treatments was 2.18. Data with average follow-up of 18 months will be presented. Conclusion:The data with average follow-up of 9 months suggest that PDT with verteporfin may lead to visual stabilization in patients with CNV who have received prior treatment with thermal laser treatment. The 18-month data will help determine if this vision stabilization is sustained for a longer period of time.

Keywords: 516 photodynamic therapy • 346 choroid: neovascularization • 357 clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×